Hepatera, Llc

Hepatera", Ltd is a private biotechnology company, founded in 2011 with the goal to develop and launch into the Russian market innovative products for treatment of liver diseases. Since December 2011 Hepatera has become a resident of Skolkovo Biomed Cluster. The first product (Myrcludex B) is aimed at treatment of chronic viral hepatitis B and, and is developed in close ooperation with a German biotech company MYR GmbH. By the end of 2011, Myrcludex B safety has been shown in the series of preclinical studies. The antiviral activity has been assessed in in vitro and in vivo experiments. In in vivo model with transplanted hepatocytes susceptible to hepatitis B virus adding Myrcludex B completely prevented establishment of a HBV infection development. In early 2012 the clinical trial phase Ia has shown the safety and well-tolerability of Myrcludex B in humans.